Double Lock of a Potent Human Monoclonal Antibody against SARS-CoV-2
Wang, X.; Qin, C.; Wang, Y.; Rao, Z.; Xie, L.; Zhu, L.; Deng, Y.-Q.; Zhang, R.-r.; Cui, Z.; Sun, C.-Y.; Fan, C.-F.; Xing, X.; Huang, W.; Chen, Q.; Zhang, N.-N.; Ye, Q.; Cao, T.-S.; Wang, N.; Wang, L.; Cao, L.; Wang, H.; Kong, D.; Ma, J.; Luo, C.; Zhang, Y.; Nie, J.; Sun, Y.; Lv, Z.; Shaw, N.; Li, Q.; Li, X.-F.; Hu, J.
Show abstract
Receptor recognition and subsequent membrane fusion are essential for the establishment of successful infection by SARS-CoV-2. Halting these steps can cure COVID-19. Here we have identified and characterized a potent human monoclonal antibody, HB27, that blocks SARS-CoV-2 attachment to its cellular receptor at sub-nM concentrations. Remarkably, HB27 can also prevent SARS-CoV-2 membrane fusion. Consequently, a single dose of HB27 conferred effective protection against SARS-CoV-2 in two established mouse models. Rhesus macaques showed no obvious adverse events when administrated with 10-fold of effective dose of HB27. Cryo-EM studies on complex of SARS-CoV-2 trimeric S with HB27 Fab reveal that three Fab fragments work synergistically to occlude SARS-CoV-2 from binding to ACE2 receptor. Binding of the antibody also restrains any further conformational changes of the RBD, possibly interfering with progression from the prefusion to the postfusion stage. These results suggest that HB27 is a promising candidate for immuno-therapies against COVID-19. HighlightsO_LISARS-CoV-2 specific antibody, HB27, blocks viral receptor binding and membrane fusion C_LIO_LIHB27 confers prophylactic and therapeutic protection against SARS-CoV-2 in mice models C_LIO_LIRhesus macaques showed no adverse side effects when administered with HB27 C_LIO_LICryo-EM studies suggest that HB27 sterically occludes SARS-CoV-2 from its receptor C_LI
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Structural Basis for Potent Neutralization of Betacoronaviruses by Single-domain Camelid Antibodies 97%
- Neutralizing and protective human monoclonal antibodies recognizing the N-terminaldomain of the SARS-CoV-2 spike protein 96%
- Structures of potent and convergent neutralizing antibodies bound to the SARS-CoV-2 spike unveil a unique epitope responsible for exceptional potency 96%
Similar papers in this journal
Similar papers in this journal
- Fortuitous Somatic Mutations during Antibody Evolution Endow Broad Neutralization against SARS-CoV-2 Omicron Variants 98%
- Potent neutralization of SARS-CoV-2 variants of concern by an antibody with a unique genetic signature and structural mode of spike recognition 96%
- Molecular basis of sarbecovirus evolution and receptor tropism in natural hosts, potential intermediate hosts, and humans 96%
Similar papers in this journal
- A combination of potently neutralizing monoclonal antibodies isolated from an Indian convalescent donor protects against the SARS-CoV-2 delta variant 97%
- Mutation Y453F in the spike protein of SARS-CoV-2 enhances interaction with the mink ACE2 receptor for host adaption 96%
- Mutations from bat ACE2 orthologs markedly enhance ACE2-Fc neutralization of SARS-CoV-2 96%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.